Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) is secreted by intestinal L‐cells following food intake, and plays an important role in glucose homeostasis due to its stimulation of glucose‐dependent insulin secretion. Further, GLP‐1 is also associated with protective effects on pancreatic β‐cells and the cardiovascular system, decreased appetite, and weight loss, making GLP‐1 derivatives an exciting treatment for type 2 diabetes and obesity. Despite these benefits, wild‐type GLP‐1 exhibits a short circulation time due to its poor metabolic stability and rapid renal clearance, and must be administered by injection, making it a poor therapeutic agent. Many strategies have been used to improve the circulation time of GLP‐1 (e.g., mutations, unnatural amino acids, depot formulations, use of exendin‐4 sequences, and fusions with high‐molecular‐weight proteins or polymers), with its therapeutic utility further improved by adding agonist activity for gastric inhibitory peptide and glucagon receptors. This minireview focuses on strategies that have been used to improve the pharmacokinetics of GLP‐1 and provides an overview of GLP‐1‐based therapeutics in the pipeline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It enhances glucose-dependent insulin secretion from pancreatic β-cells [32], stimulates somatostatin secretion from δ-cells, which suppresses glucagon secretion from α-cells [31], and exerts cytoprotective effects on β-cells by inhibiting apoptosis, inducing proliferation, and supporting insulin biosynthesis [31,36]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [36]
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.004 · Cited by 814
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Kim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 446
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
Deacon, C. F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O., & Holst, J. J. (1998) · Diabetologia · doi:10.1007/s001250050903 · Cited by 303
The structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201
Manandhar, B., & Ahn, J.-M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 198
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189
Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
van Witteloostuijn, S. B., Pedersen, S. L., & Jensen, K. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600374 · Cited by 183
Protein–polymer conjugation — moving beyond PEGylation
Qi, Y., & Chilkoti, A. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.08.009 · Cited by 176
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development
Ivens, I. A., Achanzar, W., Baumann, A., Brändli-Baiocco, A., Cavagnaro, J., Dempster, M., Depelchin, B. O., Irizarry Rovira, A. R., Dill-Morton, L., Lane, J. H., et al. (2015) · Toxicologic Pathology · doi:10.1177/0192623315591171 · Cited by 158
Choi, S., Baudyš, M., & Kim, S. W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026435.27086.94 · Cited by 150
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 141
Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
SCHJOLDAGER, B. T. G., BALDISSERA, F. G. A., MORTENSEN, P. E., HOLST, J. J., & CHRISTIANSEN, J. (1988) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1988.tb01046.x · Cited by 134
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 127
Incretin hormone mimetics and analogues in diabetes therapeutics
Green, B. D., & Flatt, P. R. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.003 · Cited by 125
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123
Synthesis, Characterization, and Pharmacokinetic Studies of PEGylated Glucagon-like Peptide-1
Lee, S., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., & Lee, K. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049735+ · Cited by 123
Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Dutt Vadlapudi, A., Krishna Vadlapatla, R., & K. Mitra, A. (2012) · Current Drug Targets · doi:10.2174/138945012800675650 · Cited by 118
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.155 · Cited by 103
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
Hui, H., Zhao, X., & Perfetti, R. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.553 · Cited by 97
Jimenez‐Solem, E., Rasmussen, M. H., Christensen, M., & Knop, F. K. (2010) · PubMed · Cited by 89
Yaturu, S. (2011) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2011.14012 · Cited by 88
Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function
Koole, C., Pabreja, K., Savage, E. E., Wootten, D., Furness, S. G. B., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120236 · Cited by 75
Drug release testing methods of polymeric particulate drug formulations
Amatya, S., Park, E. J., Park, J. H., Kim, J. S., Seol, E., Lee, H., Choi, H., Shin, Y.-H., & Na, D. H. (2013) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-013-0072-5 · Cited by 71
Lessons learned from the clinical development of oral peptides
Karsdal, M. A., Riis, B. J., Mehta, N., Stern, W., Arbit, E., Christiansen, C., & Henriksen, K. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12557 · Cited by 63
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M. A., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 56
Youn, Y. S., Chae, S. Y., Lee, S., Kwon, M. J., Shin, H. J., & Lee, K. C. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.07.009 · Cited by 48
Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect
Hanato, J., Kuriyama, K., Mizumoto, T., Debari, K., Hatanaka, J., Onoue, S., & Yamada, S. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.013 · Cited by 45
Spiegelberg, H. L., & Fishkin, B. G. (1972) · PubMed · Cited by 44
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
Liu, B., Dong, Q., Wang, M., Shi, L., Wu, Y., Yu, X., Shi, Y., Shan, Y., Jiang, C., Zhang, X., et al. (2010) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.58.1474 · Cited by 41
Zhou, J., Cai, X., Huang, X., Dai, Y., Sun, L., Zhang, B., Yang, B., Lin, H., Huang, W., & Qian, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.046 · Cited by 40
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 33
Once-weekly albiglutide in the management of type 2 diabetes: patient considerations
Anderson, S. L., & Woodward, H. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s53075 · Cited by 29
Lim, S. M., Eom, H., Jiang, H. H., Sohn, M., & Lee, K. C. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24238 · Cited by 28
Simonsen, L., Holst, J. J., Madsen, K., & Deacon, C. F. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2012.12.012 · Cited by 26
de Menthière, C. S., Chavanieu, A., Grassy, G., Dalle, S., Salazar, G., Kervran, A., Pfeiffer, B., Renard, P., Delagrange, P., Manéchez, D., et al. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.02.002 · Cited by 24
Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)
Park, E. J., Lim, S. M., Lee, K. C., & Na, D. H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1192130 · Cited by 22
Eldor, R., Kidron, M., Greenberg-Shushlav, Y., & Arbit, E. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400629 · Cited by 19
Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists
Jones, L. H., & Price, D. A. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00002-8 · Cited by 17
All in one: Researchers create combination drugs for diabetes and obesity
Chakradhar, S. (2016) · Nature Medicine · doi:10.1038/nm0716-694 · Cited by 15
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
Gallwitz, B. (2015) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2015.11.01.21 · Cited by 9
Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes
Krause, B. A., & Kirwin, J. L. (2010) · Cited by 5
Liraglutide, a GLP‐1 Analogue to Treat Diabetes
Knudsen, L. B. (2010) · Wiley eBooks · doi:10.1002/9783527630035.ch14 · Cited by 2
Kalam, N., Churi, S., Shafique, A., Ali, M., Abdi, S. A. H., & Alam, M. (2014) · International Journal of Medicine and Public Health · doi:10.4103/2230-8598.133108 · Cited by 2
Research works printed but not linked: 9
- Krause A., 2010, Formulary, 45, 43
- Jackson S. H., 2010, Pharmacy Ther., 35, 498
- Willard F. S., 2012, Exp. Diabetes Res., 470851
- Woodward H. N., 2014, Patient Preference Adherence, 8, 789
- Pratley R. E., 2014, Diabetes Endocrinol., 2, 289
- Spiegelberg H., 1972, Clin. Exp. Immunol., 10, 599
- Jimenez-Solem E., 2010, Curr. Opin. Mol. Ther., 12, 790
- Davies M. L., 2016, Austin J. Endocrinol. Diabetes, 3, 1053
- 10.1021/bc049735 · doi:10.1021/bc049735
Cited by
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
Muscogiuri, G., Barrea, L., Faggiano, F., Maiorino, M. I., Parrillo, M., Pugliese, G., Ruggeri, R. M., Scarano, E., Savastano, S., Colao, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01574-9 · Cited by 128
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Self-citationDissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
“Nonetheless, the pharmacological activation of the GLP-1R is clinically beneficial (179), offering an improved glycaemic control with lower cardiovascular morbidity and without the risk of hypoglycaemia associated with some current anti diabetic drugs (173).”
Background
Metadata
- Authors
- Cheang, J. Y., & Moyle, P. M.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Moyle, Peter M.
- ORCID
- Moyle, Peter M.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2018-02-28
- Volume
- 13
- Issue
- 7
- Pages
- 662-671
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2792698729
- Cited by
- 82
- References
- 73
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 16 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 13 · 2019: 11 · 2018: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ChemMedChem (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Queensland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, type 2 diabetes, obesity, pharmacokinetics, GLP-1 analogues, exendin-4, glucose-dependent insulinotropic polypeptide, glucagon receptor, pancreatic beta-cell protection, glucose homeostasis, insulin secretion
- MeSH terms
- Liraglutide, Exenatide, Animals, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Half-Life, Humans, Hypoglycemic Agents, Structure-Activity Relationship, Peptide Hormones, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.